BRIEF-Adaptimmune Therapeutics says initiated study of NY-ESO SPEAR T‑cells
May 25, 2017 at 08:14 AM EDT
* Adaptimmune Therapeutics Plc - initiated study of NY-ESO SPEAR T-cells targeting NY-ESO in combination with keytruda in patients with multiple myeloma